361 related articles for article (PubMed ID: 20933299)
1. Treatment of pachydermoperiostosis pachydermia with botulinum toxin type A.
Ghosn S; Uthman I; Dahdah M; Kibbi AG; Rubeiz N
J Am Acad Dermatol; 2010 Dec; 63(6):1036-41. PubMed ID: 20933299
[TBL] [Abstract][Full Text] [Related]
2. Noninferiority of incobotulinumtoxinA, free from complexing proteins, compared with another botulinum toxin type A in the treatment of glabellar frown lines.
Sattler G; Callander MJ; Grablowitz D; Walker T; Bee EK; Rzany B; Flynn TC; Carruthers A
Dermatol Surg; 2010 Dec; 36 Suppl 4():2146-54. PubMed ID: 21134045
[TBL] [Abstract][Full Text] [Related]
3. Antibody-induced failure of botulinum toxin a therapy in cosmetic indications.
Dressler D; Wohlfahrt K; Meyer-Rogge E; Wiest L; Bigalke H
Dermatol Surg; 2010 Dec; 36 Suppl 4():2182-7. PubMed ID: 21134050
[TBL] [Abstract][Full Text] [Related]
4. Botulinum toxin type a for facial rejuvenation: treatment evolution and patient satisfaction.
Sepehr A; Chauhan N; Alexander AJ; Adamson PA
Aesthetic Plast Surg; 2010 Oct; 34(5):583-6. PubMed ID: 20383497
[TBL] [Abstract][Full Text] [Related]
5. OnabotulinumtoxinA treatment of mild glabellar lines in repose.
Carruthers A; Carruthers J; Lei X; Pogoda JM; Eadie N; Brin MF
Dermatol Surg; 2010 Dec; 36 Suppl 4():2168-71. PubMed ID: 21134048
[TBL] [Abstract][Full Text] [Related]
6. Facial rejuvenation after intradermal botulinum toxin: is it really the botulinum toxin or is it the pricks?
Kapoor R; Shome D; Jain V; Dikshit R
Dermatol Surg; 2010 Dec; 36 Suppl 4():2098-105. PubMed ID: 21134041
[TBL] [Abstract][Full Text] [Related]
7. Primary and adjunctive uses of botulinum toxin type A in the periorbital region.
Balikian RV; Zimbler MS
Facial Plast Surg Clin North Am; 2005 Nov; 13(4):583-90, vii. PubMed ID: 16253845
[TBL] [Abstract][Full Text] [Related]
8. Gummy smile and botulinum toxin: a new approach based on the gingival exposure area.
Mazzuco R; Hexsel D
J Am Acad Dermatol; 2010 Dec; 63(6):1042-51. PubMed ID: 21093661
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety evaluation of a novel botulinum toxin topical gel for the treatment of moderate to severe lateral canthal lines.
Brandt F; O'Connell C; Cazzaniga A; Waugh JM
Dermatol Surg; 2010 Dec; 36 Suppl 4():2111-8. PubMed ID: 21134043
[TBL] [Abstract][Full Text] [Related]
10. Multicenter, randomized, parallel-group study of the safety and effectiveness of onabotulinumtoxinA and hyaluronic acid dermal fillers (24-mg/ml smooth, cohesive gel) alone and in combination for lower facial rejuvenation.
Carruthers A; Carruthers J; Monheit GD; Davis PG; Tardie G
Dermatol Surg; 2010 Dec; 36 Suppl 4():2121-34. PubMed ID: 21134044
[TBL] [Abstract][Full Text] [Related]
11. Intraoperative injection of botulinum toxin A into the orbicularis oculi muscle for the treatment of crow's feet.
Guerrissi JO
Plast Reconstr Surg; 2003 Oct; 112(5 Suppl):161S-163S. PubMed ID: 14504499
[No Abstract] [Full Text] [Related]
12. Commentary: Efficacy and safety of a novel botulinum toxin topical gel.
West TB
Dermatol Surg; 2010 Dec; 36 Suppl 4():2119-20. PubMed ID: 21244565
[No Abstract] [Full Text] [Related]
13. Update on botulinum toxin.
Flynn TC
Semin Cutan Med Surg; 2006 Sep; 25(3):115-21. PubMed ID: 17055389
[TBL] [Abstract][Full Text] [Related]
14. Predicting migraine responsiveness to botulinum toxin type A injections.
Kim CC; Bogart MM; Wee SA; Burstein R; Arndt KA; Dover JS
Arch Dermatol; 2010 Feb; 146(2):159-63. PubMed ID: 20157026
[TBL] [Abstract][Full Text] [Related]
15. Comparison of two botulinum toxin type A preparations for treating crow's feet: a split-face, double-blind, proof-of-concept study.
Prager W; Wissmüller E; Kollhorst B; Williams S; Zschocke I
Dermatol Surg; 2010 Dec; 36 Suppl 4():2155-60. PubMed ID: 21134046
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety evaluation of a novel botulinum toxin topical gel for the treatment of moderate to severe lateral canthal lines.
Brandt F
Dermatol Surg; 2011 Jul; 37(7):1060. PubMed ID: 21711409
[No Abstract] [Full Text] [Related]
17. Safety and efficacy of administering abobotulinumtoxinA through a single injection point when treating lateral periocular rhytides.
Kiripolsky MG; Goldman MP
J Cosmet Dermatol; 2011 Sep; 10(3):232-4. PubMed ID: 21896136
[TBL] [Abstract][Full Text] [Related]
18. [Pachydermoperiostosis (Touraine-Solente-Golé syndrome). Case report].
Santos-Durán JC; Yuste-Chaves M; Martínez-González O; Alonso-San Pablo MT; Sánchez-Estella J
Actas Dermosifiliogr; 2007 Mar; 98(2):116-20. PubMed ID: 17397600
[TBL] [Abstract][Full Text] [Related]
19. IncobotulinumtoxinA in esthetics.
Kerscher M; Yutskovskaya Y; Flynn TC
J Drugs Dermatol; 2013 Jun; 12(6):e111-20. PubMed ID: 23839200
[TBL] [Abstract][Full Text] [Related]
20. Multicenter, randomized, parallel-group study of onabotulinumtoxinA and hyaluronic acid dermal fillers (24-mg/ml smooth, cohesive gel) alone and in combination for lower facial rejuvenation: satisfaction and patient-reported outcomes.
Carruthers J; Carruthers A; Monheit GD; Davis PG
Dermatol Surg; 2010 Dec; 36 Suppl 4():2135-45. PubMed ID: 21070457
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
